CSL (OTCMKTS:CSLLY) Downgraded by Zacks Research to Strong Sell

Zacks Research cut shares of CSL (OTCMKTS:CSLLY) from a hold rating to a strong sell rating in a research note issued to investors on Monday,Zacks.com reports.

CSL Trading Down 0.8%

OTCMKTS:CSLLY opened at $67.04 on Monday. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $78.63 and its 200 day simple moving average is $78.67. CSL has a 52-week low of $64.68 and a 52-week high of $101.44.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.